•
Mar 31, 2021

AptarGroup Q1 2021 Earnings Report

AptarGroup's Q1 2021 results showcased sales growth and adjusted EPS increase, driven by strong performance in Food + Beverage segment amidst mixed market conditions.

Key Takeaways

AptarGroup reported an 8% increase in sales to $777 million for Q1 2021, with core sales up by 1%. Adjusted earnings per share totaled $1.09, a 10% increase compared to the prior year, neutralizing currency effects. The Food + Beverage segment demonstrated strong growth, while the Pharma and Beauty + Home segments experienced varied performance due to market-specific factors and pandemic-related impacts.

Reported sales increased by 8%, with core sales growing by 1%.

Earnings per share increased to $1.24, a 48% increase compared to the prior year.

Adjusted earnings per share rose to $1.09, reflecting a 10% increase from the prior year when neutralizing currency effects.

Strong performance in the Food + Beverage segment was driven by increased demand for food dispensing closures.

Total Revenue
$777M
Previous year: $722M
+7.7%
EPS
$1.09
Previous year: $0.93
+17.2%
Total Core Sales Growth
1%
Previous year: -2%
-150.0%
Beauty + Home Core Sales Growth
-3%
Previous year: -9%
-66.7%
Food + Beverage Core Sales Growth
14%
Previous year: -2%
-800.0%
Gross Profit
$288M
Previous year: $270M
+6.6%
Cash and Equivalents
$255M
Previous year: $411M
-38.0%
Free Cash Flow
$8.3M
Previous year: $23M
-63.9%
Total Assets
$3.99B
Previous year: $3.78B
+5.7%

AptarGroup

AptarGroup

AptarGroup Revenue by Segment

Forward Guidance

Aptar expects Q2 2021 earnings per share to be in the range of $0.91 to $0.99, excluding restructuring expenses and changes in the fair value of equity investments, based on an effective tax rate range of 26% to 28%.

Positive Outlook

  • Easier comparisons to the prior year second quarter which was the period most severely impacted by pandemic lockdowns.
  • Positive mid and long-term view is unchanged, based on strong innovation and customer project pipelines.
  • Future is quite promising, and Aptar looks forward to growing each of its businesses for the long-term benefit of all stakeholders.
  • Strong innovation
  • Customer project pipelines

Challenges Ahead

  • Demand for prescription drug and consumer health care devices will remain under pressure compared to the prior year as customers continue to work off existing inventories.
  • Results to be negatively impacted by the timing of passing through higher resin and other raw material costs.
  • Current underlying demand conditions in our markets are not expected to change dramatically from what was experienced in the first quarter.
  • Higher resin costs
  • Raw material costs

Revenue & Expenses

Visualization of income flow from segment revenue to net income